U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C2H5NO2.ClH
Molecular Weight 111.528
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GLYCINE HYDROCHLORIDE

SMILES

Cl.NCC(O)=O

InChI

InChIKey=IVLXQGJVBGMLRR-UHFFFAOYSA-N
InChI=1S/C2H5NO2.ClH/c3-1-2(4)5;/h1,3H2,(H,4,5);1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C2H5NO2
Molecular Weight 75.0666
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Glycine (Cly) is a natural amino acid neurotransmitter that acts as a co-agonist at Glutamate [NMDA] receptors in the brain and is an activator of glycine receptors, GLRA1-3, GLRB. The abnormal Gly levels have been implicated in neuropsychiatric disorders. Alterations in Gly levels are implicated in several diseases of the central nervous system. Glycine was studied in phase II of clinical trials in patients with schizophrenia. The results have shown that using of glycine was associated with reduced symptoms with promising effect sizes and a possibility of improvement in cognitive function. Besides, glycine was also studied in clinical trials phase II in children with cystic fibrosis. The clinical, spirometric and inflammatory status of subjects with cystic fibrosis improved after just 8 weeks of glycine intake, suggesting that this amino acid might constitute a novel therapeutic tool for these patients. In addition, Gly was proposed as a biomarker for brain tumor malignancy. Glycine is a component of a nutrients mixture for peripheral administration to well-nourished mildly catabolic adult patients who require only short-term parenteral nutrition.

CNS Activity

Curator's Comment: Known to be CNS non-penetrant in rabbit. Human data not available.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Preventing
FREAMINE III 8.5%

Approved Use

Aminosyn, Sulfite-Free, (a crystalline amino acid solution) infused with dextrose by peripheral vein infusion is indicated as a source of nitrogen in the nutritional support of patients with adequate stores of body fat, in whom, for short periods of time, oral nutrition cannot be tolerated, is undesirable, or inadequate. SUPPLEMENTAL ELECTROLYTES, IN ACCORDANCE WITH THE PRESCRIPTION OF THE ATTENDING PHYSICIAN, MUST BE ADDED TO AMINOSYN SOLUTIONS WITHOUT ELECTROLYTES. Aminosyn can be administered peripherally with dilute (5 to 10%) dextrose solution and I.V. fat emulsion as a source of nutritional support. This form of nutritional support can help to preserve protein and reduce catabolism in stress conditions where oral intake is inadequate. When administered with concentrated dextrose solutions with or without fat emulsions, Aminosyn is also indicated for central vein infusion to prevent or reverse negative nitrogen balance in patients where: (a) the alimentary tract, by the oral, gastrostomy or jejunostomy route cannot or should not be used; (b) gastrointestinal absorption of protein is impaired; (c) metabolic requirements for protein are substantially increased as with extensive burns and (d) morbidity and mortality may be reduced by replacing amino acids lost from tissue breakdown, thereby preserving tissue reserves, as in acute renal failure.

Launch Date

1971
PubMed

PubMed

TitleDatePubMed
Selective cleavage of BLM, the bloom syndrome protein, during apoptotic cell death.
2001-04-13
Mutant mice as a model for cerebellar ataxia.
2001-04
Computed free energy differences between point mutations in a collagen-like peptide.
2001-03
Glycine reduces novelty- and methamphetamine-induced locomotor activity in neonatal ventral hippocampal damaged rats.
2001-03
Functional coexpression of excitatory mGluR1 and mGluR5 on striatal cholinergic interneurons.
2001-03
(S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord.
2001-03
Evidence for microvesicular storage and release of glycine in rodent pinealocytes.
2001-02-16
Trimethylamine oxide counteracts effects of hydrostatic pressure on proteins of deep-sea teleosts.
2001-02-15
Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes.
2001-02-15
Critical role of the residue size at position 87 in H2O2- dependent substrate hydroxylation activity and H2O2 inactivation of cytochrome P450BM-3.
2001-02-09
Replacement of the axial histidine ligand with imidazole in cytochrome c peroxidase. 1. Effects on structure.
2001-02-06
Spectral integration in the inferior colliculus: role of glycinergic inhibition in response facilitation.
2001-02-01
Towards developing a non-SnCl2 formulation for RP444, a new radiopharmaceutical for thrombus imaging.
2001-02
The effect of amino acid spacers on the antigenicity of dimeric peptide--inducing cross-reacting antibodies to a cell surface protein antigen of Streptococcus mutans.
2001-02
The folate cycle and disease in humans.
2001-02
Functional projection distances of spinal interneurons mediating reciprocal inhibition during swimming in Xenopus tadpoles.
2001-02
Distribution of transcripts for the brain-specific GDP/GTP exchange factor collybistin in the developing mouse brain.
2001-02
Atypical neural messengers.
2001-02
High-dose intravenous infusion of irrigating fluids containing glycine and mannitol in the pig.
2001-02
Selective blockade of the mGluR1 receptor reduces traumatic neuronal injury in vitro and improvesoOutcome after brain trauma.
2001-02
Microdialysis in Parkinsonian patient basal ganglia: acute apomorphine-induced clinical and electrophysiological effects not paralleled by changes in the release of neuroactive amino acids.
2001-02
Homeodomain leucine zipper proteins bind to the phosphate response domain of the soybean VspB tripartite promoter.
2001-02
High-affinity zinc potentiation of inhibitory postsynaptic glycinergic currents in the zebrafish hindbrain.
2001-02
Differential actions of PKA and PKC in the regulation of glutamate release by group III mGluRs in the entorhinal cortex.
2001-02
Glycine supply to human enterocytes mediated by high-affinity basolateral GLYT1.
2001-02
Amino acid interconversions in the fetal-placental unit: the animal model and human studies in vivo.
2001-02
Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma.
2001-02
A novel syndrome affecting multiple mitochondrial functions, located by microcell-mediated transfer to chromosome 2p14-2p13.
2001-02
Engineering conformational flexibility in the lactose permease of Escherichia coli: use of glycine-scanning mutagenesis to rescue mutant Glu325-->Asp.
2001-01-23
Virol A, a toxic trans-polyacetylenic alcohol of Cicuta virosa, selectively inhibits the GABA-induced Cl(-) current in acutely dissociated rat hippocampal CA1 neurons.
2001-01-19
Intracellular folding pathway of the cystine knot-containing glycoprotein hormone alpha-subunit.
2001-01-16
Intensity-dependent, rapid activation of presynaptic metabotropic glutamate receptors at a central synapse.
2001-01-15
Three pairs of cysteine residues mediate both redox and zn2+ modulation of the nmda receptor.
2001-01-15
Familial Tetralogy of Fallot caused by mutation in the jagged1 gene.
2001-01-15
Regulation of a mammalian Shaker-related potassium channel, hKv1.5, by extracellular potassium and pH.
2001-01-12
Genetics, an alternative way to discover, characterize and understand ion channels.
2001-01-12
Analysis of glycoconjugate patterns of normal and hormone-induced dysplastic Noble rat prostates, and an androgen-independent Noble rat prostate tumor, by lectin histochemistry and protein blotting.
2001-01-01
A rapid procedure for isolating chromosomal DNA from Lactobacillus species and other Gram-positive bacteria.
2001-01
Ehlers-Danlos syndrome type IV with a unique point mutation in COL3A1 and familial phenotype of myocardial infarction without organic coronary stenosis.
2001-01
New polymorphisms in the interleukin-10 gene--relationships to myocardial infarction.
2001-01
An HphI polymorphism in the E-selectin gene is associated with premature coronary artery disease.
2001-01
Generalized dystrophic epidermolysis bullosa: identification of a novel, homozygous glycine substitution, G2031S, in exon 73 of COL7A1 in monozygous triplets.
2001-01
A missense mutation encoding cys(67) --> gly in neurophysin ii is associated with early onset autosomal dominant neurohypophyseal diabetes insipidus.
2001-01
Determination of bile acids in biological fluids by liquid chromatography-electrospray tandem mass spectrometry.
2001-01
cAMP-dependent presynaptic regulation of spontaneous glycinergic IPSCs in mechanically dissociated rat spinal cord neurons.
2001-01
Postsynaptic currents in deep cerebellar nuclei.
2001-01
Slow dorsal-ventral rhythm generator in the lamprey spinal cord.
2001-01
Excitatory amino acid concentrations in ventricular cerebrospinal fluid after severe traumatic brain injury in infants and children: the role of child abuse.
2001-01
Sustained L-type calcium currents in dissociated deep dorsal horn neurons of the rat: characteristics and modulation.
2001
Temperature-dependent separation of a delayed-onset long-lasting enhancement mediated by coactivation of NMDA and metabotropic glutamate receptors following a transient exposure of extracellular high Ca(2+).
2001
Patents

Sample Use Guides

Daily oral supplement of glycine at a dose of 0.5 g/kg divided in three doses during 8 weeks
Route of Administration: Oral
The excess of glycine inhibits the growth of many bacteria, and it is used as a nonspecific antiseptic agent due to its low level of toxicity in animals. The MIC at which 90% of strains are inhibited for glycine was almost 2.5 mg/ml for 31 strains of H. pylori, including CLR-resistant strains.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:57:42 GMT 2025
Edited
by admin
on Mon Mar 31 17:57:42 GMT 2025
Record UNII
225ZLC74HX
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GLYCINE HYDROCHLORIDE
II   MI   WHO-DD  
Systematic Name English
GLYCINE HCL
INCI  
INCI  
Preferred Name English
GLYCINE HYDROCHLORIDE [II]
Common Name English
GLYCINE HYDROCHLORIDE [MI]
Common Name English
Glycine hydrochloride [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C231
Created by admin on Mon Mar 31 17:57:42 GMT 2025 , Edited by admin on Mon Mar 31 17:57:42 GMT 2025
Code System Code Type Description
CAS
6000-43-7
Created by admin on Mon Mar 31 17:57:42 GMT 2025 , Edited by admin on Mon Mar 31 17:57:42 GMT 2025
PRIMARY
FDA UNII
225ZLC74HX
Created by admin on Mon Mar 31 17:57:42 GMT 2025 , Edited by admin on Mon Mar 31 17:57:42 GMT 2025
PRIMARY
ECHA (EC/EINECS)
227-841-8
Created by admin on Mon Mar 31 17:57:42 GMT 2025 , Edited by admin on Mon Mar 31 17:57:42 GMT 2025
PRIMARY
EVMPD
SUB28876
Created by admin on Mon Mar 31 17:57:42 GMT 2025 , Edited by admin on Mon Mar 31 17:57:42 GMT 2025
PRIMARY
NCI_THESAURUS
C79999
Created by admin on Mon Mar 31 17:57:42 GMT 2025 , Edited by admin on Mon Mar 31 17:57:42 GMT 2025
PRIMARY
RXCUI
1311532
Created by admin on Mon Mar 31 17:57:42 GMT 2025 , Edited by admin on Mon Mar 31 17:57:42 GMT 2025
PRIMARY RxNorm
PUBCHEM
22316
Created by admin on Mon Mar 31 17:57:42 GMT 2025 , Edited by admin on Mon Mar 31 17:57:42 GMT 2025
PRIMARY
DAILYMED
225ZLC74HX
Created by admin on Mon Mar 31 17:57:42 GMT 2025 , Edited by admin on Mon Mar 31 17:57:42 GMT 2025
PRIMARY
EPA CompTox
DTXSID7064079
Created by admin on Mon Mar 31 17:57:42 GMT 2025 , Edited by admin on Mon Mar 31 17:57:42 GMT 2025
PRIMARY
SMS_ID
100000092434
Created by admin on Mon Mar 31 17:57:42 GMT 2025 , Edited by admin on Mon Mar 31 17:57:42 GMT 2025
PRIMARY
MERCK INDEX
m5796
Created by admin on Mon Mar 31 17:57:42 GMT 2025 , Edited by admin on Mon Mar 31 17:57:42 GMT 2025
PRIMARY Merck Index
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY